Section archive
Healthcare
Healthcare
CDC Recommends Maternal RSV Vaccine at 32–36 Weeks After 11-1 Vote, Adding Second Infant Protection Option
Healthcare
CDC Recommends Updated XBB.1.5 COVID-19 Vaccines for Everyone 6 Months and Older After 13-1 Advisory Vote
Healthcare
FDA Approves APHEXDA After Phase 3 Trial Shows 92.5% Stem-Cell Mobilization Success in Multiple Myeloma
Healthcare
Medicare Selects First 10 Drugs for Price Negotiation After $50.5 Billion in Part D Spending
Healthcare
FDA Approves First Maternal RSV Vaccine, Cutting Severe Infant Disease 81.8% in First 90 Days
Healthcare
FDA Approves Elrexfio After 57.7% Response Rate in Heavily Pretreated Multiple Myeloma
Healthcare
Wegovy Cuts Major Cardiovascular Events 20% in 17,604-Patient SELECT Trial
Healthcare
FDA Approves Zurzuvae as First Oral Postpartum Depression Drug, Using a 14-Day Treatment Course
Healthcare
Biden Administration Proposes Stronger Mental Health Parity Rules, Targeting Network and Prior-Authorization Barriers
Healthcare
FDA Approves Beyfortus to Prevent RSV in Infants With One Dose Covering a Typical Five-Month Season
Healthcare
FDA Approves Opill as First U.S. Over-the-Counter Daily Birth Control Pill, Ending Prescription Requirement
Healthcare
FDA Gives Leqembi Full Approval After 1,795-Patient Trial Shows 27% Slower Early Alzheimer’s Decline
Healthcare
CMS Finalizes First Medicare Drug-Negotiation Framework After More Than 7,500 Comments, With 10 Part D Drugs Due by September
Healthcare
CDC Advisers Back First Adult RSV Vaccines for Ages 60+, Using Shared Clinical Decision-Making
Healthcare
FDA Moves Fall COVID Vaccines to Monovalent XBB.1.5 After Advisory Panel Backs XBB-Lineage Update
Healthcare
FDA Advisers Vote 6-0 That Leqembi Confirms Clinical Benefit After 1,795-Patient Alzheimer’s Trial
Healthcare
FDA Approves Pfizer’s Abrysvo for Adults 60 and Older After 37,000-Participant RSV Trial
215 stories